Novel Drug 'Graduates' in Breast Ca Trial (CME/CE)

SAN DIEGO (MedPage Today) -- A targeted therapy for breast cancer "graduated" to phase III eligibility for patients with HER2-positive/hormone receptor-negative disease, data from an ongoing trial showed.
Source: MedPage Today Public Health - Category: American Health Source Type: news